About a quarter of people risk heart attacks and strokes because they inherited a kind of cholesterol that statin drugs can’t ...

Amgen (NasdaqGS:AMGN) experienced a significant 18.62% price increase over the last quarter, coinciding with the recent FDA ...

Shares of Amgen Inc. AMGN rallied 1.36% to $309.85 Thursday, on what proved to be an all-around dismal trading session for ...

The U.S. Food and Drug Administration has approved expanded use of Amgen's drug, Uplizna, to help reduce the risk of flares ...

Ian Thompson, SVP and general manager of U.S. business operations at Amgen, shares his leadership philosophy, what he's ...

Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Amgen is a leading biopharmaceutical company that develops innovative medicines in areas with significant unmet needs. Read ...

Piper Sandler analyst David Amsellem reiterated a Buy rating on Amgen (AMGN – Research Report) today and set a price target of $329.00. The ...

The FDA approved Amgen ’s anti-CD19 therapy Uplizna Thursday for use in patients with IgG4-related disease. Uplizna is the ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

With a label expansion for Uplizna pushing the drug into an untouched rare disease market, Amgen is getting its money’s worth ...

A federal judge has thrown out Amgen’s lawsuit against the state board empowered to set price ceilings on prescription drugs ...